Acrivon Therapeutics (ACRV) Accounts Payables (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Accounts Payables of $1.2 million for Q1 2026, down 68.52% year-over-year from $3.7 million in Q1 2025, and down 48.97% quarter-over-quarter from $2.3 million in Q4 2025.
Acrivon Therapeutics (ACRV) Accounts Payables (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Accounts Payables for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 68.52% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 68.52% YoY), while the FY2025 annual figure was $2.3 million, up 200.4% from the prior year.
- Accounts Payables retreated to $1.2 million in Q1 2026 per ACRV's latest filing, from $2.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.0 million in Q4 2023 and bottomed at $758000.0 in Q4 2024.
- Historically, Accounts Payables has averaged $1.8 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 458.41% — and 2024, when it slumped 84.98%.
- Acrivon Therapeutics' Accounts Payables stood at $904000.0 in 2022, then surged by 458.41% to $5.0 million in 2023, then plunged by 84.98% to $758000.0 in 2024, then soared by 200.4% to $2.3 million in 2025, then tumbled by 48.97% to $1.2 million in 2026.
- Business Quant data shows ACRV's Accounts Payables at $1.2 million in Q1 2026, $2.3 million in Q4 2025, and $996000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | 861,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 861,000.00 |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 2.28 Mn |
| Sep 30, 2025 | 996,000.00 |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 758,000.00 |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 2.06 Mn |
| Dec 31, 2023 | 5.05 Mn |
| Sep 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 904,000.00 |
| Sep 30, 2022 | 1.98 Mn |
| Dec 31, 2021 | 964,000.00 |